spacer
home > epc > spring 2002 > what you should expect from a user-friendly edc solution
PUBLICATIONS
European Pharmaceutical Contractor

What You Should Expect from a User-Friendly EDC Solution

'User-friendly' is one of the most commonly misunderstood phrases in the computer lexicon. For years, every software package claimed to be 'user-friendly', diluting what the term actually means. Many purchasing agents began to ignore the claim because it was so difficult to quantify. Consequently, the term all but disappeared.

However, in the world of clinical trial software, it is dangerous to ignore the term 'user-friendly' in evaluations - particularly when investigator sites place such high importance on the concept. Being 'user-friendly' is an important criteria for software selection, but the trick is defining user-friendliness in a way that meets the needs of sites.

A critical point about the EDC selection process is that, generally, the decision-makers are the sponsor companies, and often the data management team for these companies plays an important role in the choice of EDC vendor. Although it is important that EDC software meet the data management requirements, it is absolutely critical that the initial users of the software (the personnel at the investigator site and the data monitors), readily accept the software. Without the site and monitor 'buy-in', data won't be entered into the site in a timely fashion and the software won't be used effectively. Without clean data available to data management, the usefulness of EDC is minimised.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thomas Haskell, Director of Product Management at CB Technologies, Inc

Tom Haskell is Director of Product Management at CB Technologies, Inc. In this position, he is responsible for the strategic direction of the company's suite of clinical trial software products. A graduate of Harvard University, he has over 20 years of experience in software product strategy and full software life cycle development in many different industries.

Tom began his tenure at CB as a Strategic Consultant for many of the top pharmaceutical companies, including Pfizer and Aventis. Prior to joining CB, he served as Vice President and General Manager for MapQuest.com, a supplier of travel information on the Internet.

spacer
Thomas Haskell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers
 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement